This is a first-in-human study to learn more about the study drugs called RMS-6291 and RMC-6236.
This is an open-label, multicenter, Phase 1b study of RMC-6291 in combination with RMC-6236 in participants with advanced KRAS G12C-mutated solid tumors. The study has two parts: Part 1 - Dose-Escalation and Part 2 Dose-Expansion.
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.
Principal Investigator